WWW.IJRPR.COM

International Journal of Research Publication and Reviews

Journal homepage: www.ijrpr.com ISSN 2582-7421

CLINICAL TRIALS – A REVIEW

Miss. Shaikh Asiya Sikandar * , Miss Shinde Sonal *

Pratibhatai Pawar College of Pharmacy, Shrirampur
Email ID: Asiyashaikh13891@gmail.com

ABSTRACT

A clinical trial is a exploration study in mortal levies to answer specific health questions. Precisely conducted clinical trials are swift and safest way to find treatment that work in people and way to ameliorate health. Investigational trials determine whether experimental treatment or new ways of using known curatives are safe and effective under controlled terrain. experimental trials address health issues in large groups of people or population in natural settings. Clinical trials aim to measure remediveness and constitute an important and largely technical form of natural assay. In phase I pharmacokinetics, safety, gross goods are studied on mortal levies, by clinical pharmacologists.However, it enters phase II testings, where pharmacokinetics, If the medicine passes thetest.efficiency are studied on named cases by clinical pharmacist, if passes hundreds of named cases are now studied, primarily for safety and remedial effectiveness by clinical investigators in phase III. If this is passed the medicine is now approved and retailed. Indeed after marketing, croakers from colorful hospitals and conventions shoot their opinion about the medicine, regarding ADR, efficacity in phase IV.

***Keywords**: Clinical Trials, Preclinical Studies, Clinical studies, NDA.*

1. INTRODUCTION

A clinical trial is a exploration study that tests a new medical treatment or a new way of using an being treatment to see if it'll be a better way to help and screen for diagnose or treat a disease[1]. For any new medicine to enter in clinical trial, it must pass preclinical studies. Preclinical studies involve in vitro(i.e. test- tube or Laboratory) studies and trials on beast populations. Wide range of Tablets of the study medicine is given to beast subjects or to an in- vitro substrate in order to gain primary efficacity, toxin and pharmacokinetic information[2].

The explosion in fitness care charges in the United States has these days spurred massive federal investments in fitness care to become aware of the scientific redress of absolute best value. Specifically,$1.1 billion has been appropriated through the American Recovery and Reinvestment Act of 2009 for "comparative effectiveness" lookup to consider "…clinical outcomes, effectiveness,and appropriateness of items, services, and approaches that are used to prevent, diagnose, or treat diseases, disorders, and different fitness conditions."[11].

2. PHASES OF CLINICAL TRIALS

Figure 1: Phases of Clinical Trials [16]

3. PRE-CLINICAL STUDIES

Pre-clinical studies involve in vitro(i.e., test tube or laboratory) studies and trials on beast populations. Wide- ranging tablets of the study medicine are given to the beast subjects or to an in- vitro substrate in order to gain primary efficacity, toxin and pharmacokinetic information and to help pharmaceutical companies in deciding whether it's worthwhile to go ahead with farther testing.

PHASE 0:

Phase 0 is a recent designation for exploratory, first- in- mortal trials conducted in agreement with theU.S. Food and Drug Administration's(FDA) 2006 Guidance on Exploratory Investigational New Drug(IND) Studies Phase 0 trials are designed to speed up the development of promising medicines or imaging agents by establishing veritably beforehand on whether the medicine or agent behaves in mortal subjects as was anticipated from preclinical studies. Distinctive features of Phase 0 trials include the administration of single sub remedial boluses of the study medicine to a small number of subjects(10 to 15) to gather primary data on the agent's pharmacokinetics (how the body processes the medicine) and pharmacodynamics(how the medicine works in the body).

PHASE I:

Phase I trials are the first stage of testing in mortal subjects. typically, a small(20- 80) group of healthy levies will be named. This phase includes trials designed to assess the safety(pharmacovigilance), tolerability, pharmacokinetics, and pharmacodynamics of a medicine. These trials are frequently conducted in an outpatient clinic, where the subject can be observed by full- time staff. The subject who receives the medicine is generally observed until several half- lives of the medicine have passed. Phase I trials also typically include cure- ranging, trial called cure escalation, studies so that the applicable cure for remedial use can be set up. The tested range of boluses will generally be a bit of the cure that causes detriment in Beast testing. Phase I trials most frequently include healthy levies. still, there are some circumstances when real cases are used, similar as cases who have end- stage complaint and warrant other treatment options. This exception to the rule most frequently occurs in oncology(cancer) and HIV medicine trials. Levies are paid an vexation figure for their time spent in the levy centre. Pay ranges from a small quantum of plutocrat for a short period of hearthstone, to a larger quantum of over to approx £ 4.000 depending on length of participation,

There are different kinds of Phase I trials:

1. **SAD:**

   Single Ascending Cure studies are those in which small groups of subjects are given a single cure of the medicine while they're observed and tested for a period of time. If they don't parade any adverse side goods, and the pharmacokinetic data is roughly in line with prognosticated safe values, the cure is escalated, and a new group of subjects is also given a advanced cure. This is continued until pre- calculated pharmacokinetic safety situations are reached, or intolerable side goods start showing up at which point the medicine is said to have reached the Maximum permitted cure (MTD).

2. **MAD:**

   Multiple Ascending Cure studies are conducted to more understand the pharmacokinetics & pharmacodynamics of multiple boluses of the medicine.

PHASE II:

Once the original safety of the study medicine has been verified in Phase I trials, Phase II trials are performed on larger groups(20- 300) and are designed to assess how well the medicine workshop, as well as to continue Phase I safety assessments in a larger group of levies and cases. When the development process for a new medicine fails, this generally occurs during Phase II trials when the medicine is discovered not to work as planned, or to have poisonous goods. Phase II studies are occasionally divided into Phase IIA and Phase IIB. Phase IIA is specifically designed to assess dosing conditions(how important medicine should be given), whereas Phase IIB is specifically designed to study efficacity(how well the medicine works at the specified cure(s)). Some trials combine Phase I and Phase II, and test both efficacity and toxin.

PHASE III:

Phase III studies are randomized controlled multicenter trials on large patient groups(300 – or further depending upon the complaint/ medical condition studied) and are aimed at being the definitive assessment of how effective the medicine is, in comparison with current' gold standard' treatment. Because of their size and comparatively long duration, Phase III trials are the most Precious, time- consuming and delicate trials to design and run, especially in curatives for habitual medical conditions. It's common practice that certain Phase III trials will continue while the nonsupervisory submission is pending at the applicable nonsupervisory agency. While not needed in all cases, it's generally anticipated that there be at least two successful Phase III trials, demonstrating a medicine's safety and efficacity, in order to Gain blessing from the applicable nonsupervisory agencies FDA(USA), TGA(Australia), EMEA(European Union), etc.). Once a medicine has proved satisfactory after Phase III trials, the trial results are generally combined into a large document containing a comprehensive description of the styles and results of mortal and beast studies, manufacturing procedures, expression details, and shelf life. This collection of information makes up the " nonsupervisory submission" that's handed

for review to the applicable nonsupervisory authorities in different countries. utmost medicines witnessing Phase III clinical trials can be Retailed under FDA morals with proper recommendations and guidelines, but in case of any adverse goods being reported anywhere, the medicines need to be recalled incontinently from the request. While utmost pharmaceutical companies refrain from this practice, it isn't abnormal to see numerous medicines witnessing Phase III clinical trials in the request.

PHASE IV:

Phase IV trial is also known as Post Marketing Surveillance Trial. Phase IV trials involve the safety surveillance(pharmacovigilance) and ongoing specialized support of a medicine after it receives authorization to be vended. Phase IV studies may be needed by nonsupervisory authorities or may be accepted by the financing company for competitive(chancing a new request for the medicine) or other reasons(for illustration, the medicine may not have been tested for relations with other medicines, or on certain population groups similar as pregnant women, who are doubtful to subject themselves to trials). The safety surveillance is designed to descry any rare or long- term adverse goods over a much larger case population and longer time period than was possible during the Phase I- III clinical trials. dangerous goods discovered by Phase IV trials may result in a medicine being no longer vended, or confined to certain uses recent exemplifications involve cerivastatin(brand names Baycol and Lipobay), troglitazone(Rezulin) and rofecoxib(Vioxx) [2].

4. INVESTIGATIONAL NEW DRUG (IND)/ CLINICAL TRIAL EXCEPTION(CTX)/ CLINICAL TRIAL AUTHORIZATION(CTA) APPLICATION

INDs (in theU.S.), CTXs(in theU.K.) and CTAs(in Australia) are exemplifications of requests submitted to applicable nonsupervisory authorities for authorization to conduct investigational exploration. This exploration can include testing of a new lozenge form or new use of a medicine formerly approved to be retailed. In addition to carrying authorization from applicable nonsupervisory authorities, an Institutional or Independent Review Board(IRB) OR Ethical Advisory Board must Authorize the protocol for testing as well as the informed concurrence documents that volunteers sign previous to Sharing in a clinical study. An IRB is an independent commission of croakers, community lawyers and others that ensures a clinical trial is ethical and the rights of study actors are defended. NEW Medicine operation(NDA)/ MARKETING AUTHORIZATION operation(MAA) NDAs(in theU.S.) and MAAs(in theU.K.) are exemplifications of operations to request a new medicine. similar operation document safety and efficacity of the investigational medicine and contain all the information collected during the medicine development process. At the conclusion of successful preclinical and clinical testing, this series of documents is submitted to the FDA in theU.S. or to the applicable nonsupervisory authorities ion other countries. The operation must present substantial substantiation that the medicine will have the effect it's represented to have when people use it or under the conditions for which it's specified recommended or suggested in the labeling. carrying blessing to vend a new medicine constantly takes between six months and two years[4].

5. TYPES OF CINICAL TRIAL

1. **Treatment trials:**

Test experimental treatments, new combinations of medicines, or new approaches to surgery or radiation remedy.

2. **Prevention trials:**

Look for better ways to help complaint in people who have noway had the complaint or to help a complaint from returning. These approaches may include drugs, vitamins, vaccines, minerals, or life changes.

3. **Diagnostic trials:**

Conducted to find better tests or procedures for diagnosing a particular complaint or condition,

4. **Screening trials:**

Test the stylish way to descry certain conditions or health conditions.

6. QUALITY OF LIFE

Trials (or probative Care trials) explore ways to ameliorate comfort and the quality of life for individualities with a habitual illness[2].

MONITORING CLINICAL TRIALS:

The purposes of trial monitoring are to corroborate that

1. The rights and well being of mortal subjects are defended.
2. The reported trial data are defended.

3. The conduct of the trial is in compliance with the presently approved protocol/ correction(s), with GCP, and with the applicable nonsupervisory Demand(s).

ETHICAL CONSIDERATION:

An Independent body(a review board or a commission, institutional, indigenous, public, or supranational), constituted of medical professionals and non- medical members, whose responsibility it's to insure the protection of the rights, safety and well- being of mortal subjects involved in a trial and to give public assurance of that protection, by among other effects, reviewing and approving/ furnishing favorable opinion on, the trial protocol, the felicity of the investigators installations, and the styles and material to be used in carrying and establishing informed concurrence of the trial subjects. The legal status, composition, function, operations and nonsupervisory conditions pertaining to Independent Ethics panels may differ among countries, but should allow the independent Ethics Committee to act in agreement with GCP as described in this guideline.

COMPLIANCE WITH PROTOCOL:

The investigator/ institution should conduct the trial in compliance with the protocol agreed to by the guarantor and, if needed, by the nonsupervisory authority(ies) and which were given blessing/ favourable opinion by the IRB/ IEC. The investigator/ institution and the guarantor should subscribe the protocol, or an indispensable contract, to confirm agreement. The investigator shouldn't apply in divagation from, or changes of the protocol without agreement by the guarantor and previous review and proved blessing/ favorable opinion from the IRB/ IES of an correction, except where necessary to exclude an immediate hazard(s) to trial subject, or when the change(s) involves only logistical or executive aspect of the trial(e.g. change in examiner(s), change of telephone no.(s). The investigator, or person designated by the investigator, should document and explain any divagation from the approved protocol. The investigator may apply a divagation from, or a change of the protocol to exclude an immediate hazard(s) to trial subjects without previous IRB/ IEC blessing/ favorable opinion. As soon as possible, the enforced divagation or change, the reasons for it, and if applicable, the proposed protocol correction(s) should be submitted.

1. To the IRB/ IEC for review and blessing/ favorable opinion.
2. To the guarantor for agreement.
3. To the nonsupervisory authority(IES).

7. PLANS OF CLINICAL TRIALS

Trials may be open, eyeless or double-eyeless.

1. Open trial :

In an open trial, the experimenter knows the full details of the treatment and so does the case. These trials are open to challenge for bias, and they do nothing to reduce the placebo effect. still, occasionally they're necessary, as placebo treatments aren't always possible(see Blinding). generally this kind of study design is used in bioequivalence studies.

2. Eyeless trials :

Single-eyeless trial In a single-eyeless trial, the experimenter knows the details of the treatment but the case does not. Because the case does not know which treatment is being administered(the new treatment or another treatment) there might be no placebo effect. In practice, since the experimenter knows, it's possible for him to treat the case else or to subconsciously hint to the case important treatment- affiliated details, therefore impacting the outgrowth of the study.

3. Double-eyeless trial :

In a double-eyeless trial, one experimenter allocates a series of Figures to' new treatment' or' old treatment'. The alternate experimenter is told the figures, but not what they've been allocated to. Since the alternate experimenter doesn't know, he can not conceivably tell the case, directly or Else, and can not give in to patient pressure to give him the new treatment. In this system, there's also frequently a more realistic distribution of relations and periods of cases. thus double-eyeless(or randomized) trials are preferred, as they tend to give the most accurate results.

4. Triple-eyeless trial :

Some randomized controlled trials are considered triadic- dazed, although the meaning of this may vary according to the exact study design. The most common meaning is that the subject, experimenter and person administering the treatment(frequently a druggist) are dazed to what's being given. Alternatively, it may mean that the case, experimenter and statistician are dazed. The platoon covering the response may be ignorant of the intervention being given in the control and study groups. These fresh preventives are frequently in place with the further generally accepted term" double eyeless trials", and therefore the term " triple- dazed" is rarely used. still, it connotes an fresh subcaste of security to help overdue influence of study results by anyone directly involved with the study[6].

ETHICAL CONDUCT:

Clinical trials are nearly supervised by applicable nonsupervisory authorities. All studies that involve a medical or Remedial intervention on cases must be approved by a supervising ethics commission before authorization is granted to run the trial. The original ethics commission has discretion on how it'll supervise nonintervention studies (experimental studies or those using formerly collected data). In theU.S., this body is called the Institutional Review Board(IRB). utmost caricatures are located at the original investigator's sanitarium or institution, but some guarantors allow the use of a central(independent/ for profit) IRB for investigators who work at lower institutions. To be ethical, experimenters must gain the full and informed concurrence of sharing mortal subjects.(One of the Rib's main functions is icing that implicit cases are adequately informed about the clinical trial.) If the case is unfit to assent for him/ herself, experimenters can seek concurrence from the case's fairly authorized representative. In California, the state has prioritized the Individualities who can serve as the fairly authorized representative.

In someU.S. locales, the original IRB must certify experimenters and their staff before they can conduct clinical trials. They must the civil patient sequestration HIPAA) law and good clinical practice. International Conference of Harmonization Guidelines for Good Clinical Practice(ICH GCP) is a set of norms used internationally for the conduct of clinical trials. The guidelines aim to insure that the" rights, safety and well being of trial subjects are defended". The protestation of Helsinki of the World Medical Association(1964) codifies recommendation for guidance of croakers in clinical research[7].

8. ICH GCP GUIDELINES

The headliners of ICH GCP--

1. Clinical trial should be conducted in agreement with the ethical headliners that have their origin in the protestation of Helsinki, and that are harmonious with GCP and the applicable nonsupervisory demand.

2. Before a trial is initiated, foreseeable pitfaresearch nuisances should be counted against the awaited benefit for the individual trial subject and society. A trial should be initiated and continued only if the anticipated benefits justify the pitfalls.

3. The rights, safety, and well being of the trial subjects are the most important considerations and should prevail over interests of wisdom and society.

4. The available nonclinical and clinical information on an investigational product should be acceptable to support the proposed clinical trial.

5. Clinical trials should be scientifically sound, and described in a clear, detailed protocol.

6. A trial should be conducted in compliance with the protocol that has entered previous institutional review board(IRB) independent ethics commission(IEC) Blessing/ favorable opinion.

7. The medical care given to and medical opinions made on behalf of, subjects should always be the responsibility of a good croaker , or when Applicable, of a good dentist.

8. Each existent involved in conducting a trial should be qualified by education, training, and experience to perform his or her separate tasks.

9. Freely given informed concurrence should be attained from every subject previous to clinical trial participation.

10. All clinical trial information should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation and verification.

11. The confidentiality of records that could identify subjects should be defended, esteeming the sequestration and confidentiality rules in agreement with the applicable Nonsupervisory demand.

12. Investigational products should be manufactured, handled, and stored in agreement with applicable good manufacturing practice(GMP). They should be used in agreement with the blessing protocol.

13. Systems with procedures that assure the quality of every aspect of the trial should be implante prescribe

9. INTERNATIONAL CONFERENCE ON HARMONIZATION GUIDELINES

In Recognition of the transnational request place for medicinal and in an trouble to achieve global Effectiveness for both nonsupervisory agencies and the pharmaceutical assiduity, the FDA, counterpart agencies of the European Union and Japan and geographic representatives of the pharmaceutical assiduity formed a Triplex association in 1991 to bandy, identify, and address applicable nonsupervisory issues. This association, named the transnational conference on Adjustment of medicinals for mortal Use(ICH) has worked toward harmonizing, or bringing together, nonsupervisory conditions with the long- range thing of establishing a livery set of norms for medicine enrollment within these geographic areas. With ICH success, reiterative specialized conditions for registering medicinals would be excluded, new medicine blessings would do more fleetly, cases ' access to new drugs would be enhanced worldwide, the quality, safety, and efficacity of imported products would be bettered, and there would be an increase in information transfer between sharing countries. The ICH's work toward livery norms is concentrated on three general areas, quality, safety and efficacity. The quality content includes stability, light stability, logical confirmation, contaminations, and biotechnology. The safety motifs include carcinogenicity, genotoxicity, toxicokinetics, reduplication toxin and single and repeat- cure toxin. The efficacity motifs include population

exposure, managing clinical trials, clinical study reports, cure response, ethic factors, good clinical practices, and elders. For each content, applicable regulations are linked, addressed and agreement guidelines developed. The intension is that these guidelines will be incorporated in to domestic regulations. In the United states the performing guidelines are published in the Federal Register as notices, with coexisting statements indicating that the guideline should be " Useful " or " considered " by Aspirants conducting needed studies or submitting enrollment operations.

Exemplifications of specific ICH developed guidelines:

1. Stability testing of new medicine substances and products
2. confirmation of logical procedures for medicinals
3. contaminations in new medicine substances and products
4. General consideration for clinical trial[8].

10. PART OF PLACEBO

Placebo is a Latin term which means " I may please you. " The placebo effect is an effect attributable to a cure as a procedure, and isn't due to any specific pharmacodynamic property of the substance for the condition being treated. Placebo effect may be defined as " how the cases perception of treatment influences his/ her response. " Placebos are used, During the clinical trial, to exclude the possibility that the benefit of the medicine is solely due to chance; and as remedial agents that work psychologically.

A placebo medication is generally an inert substance like bounce or lactose. still sometimes it may be a medicine that's active but in a different situation. In fact, indeed when an active medicine is used, its placebo effect frequently comforts the patient important before the Medicine is effective. It's well known that the case as well as his cousins get some immediate relief as soon as the croaker 's drug is administered, irrespective of its medicine content. This is because of their faith in the croaker that effects will go well in his hands. Placebos can frequently produce relief of private symptoms associated with cerebral disturbances. This includes relief from anxiety, headache, pain, wakefulness and breathlessness. Hence placebos are frequently employed in the treatment of certain conditions where the psychic element is suspected to be responsible for Private symptoms. ideal responses similar as increase or drop in Europhiles and eosinophils may occasionally be seen with placebos. When administered for its remedial goods, the placebo Medication, must appear to be applicable to the illness, must be inoffensive, Should rather conform to the case's prospects and To be effective, the ' energy ' of the medication must be shown by some signs similar as strong taste, a various capsule or a tablet of odd shape and occasionally indeed by egregious but inoffensive lateral effect like colored urine. During clinical trials, placebos are used to exclude the effect of bias of the croaker and the case, particularly in assessing a new medicine claimed to be effective in conditions like bronchial asthma, angina pectoris, pain and psychiatric diseases. In similar cases the placebo should be indistinguishable from the active cure in physical assets like color, smell, taste and form. Placebo effect may be modified by

1. Personality of the croaker
2. Personality of the case.
3. Form of administration [9].

11. PART OF DRUGGISTS IN CLINICAL TRIALS

Druggists have an active part to play in exploration and clinical trials first of all, we give the necessary installations needed for proper storehouse of the investigational medicinal products(IMPs), either in the fridge or at controlled room temperature. Regular temperature monitoring is assured and recorded. It's also the druggist's duty to insure there's constant force of IMPs at all times, and that they're allocated to cases consequently. Cases are counselled on the correct use of the IMPs in addition to any spoken information that is handed, similar as, Informed Consent Form or the Case Information Leaflet. IMPs returns from cases are counted and proved to determine compliance to the treatment. For fit suitable IMPs, druggists will also insure that they're prepared in agreement to the specifications quested in the trial, and that they're administered meetly.

Besides managing clinical trials, oncology druggists frequently run exploration systems that are aimed at perfecting issues in cases who admit specifics, similar as chemotherapy or other probative medicines likeanti-emetics, blood growth factor injections,etc. medicine Application Evaluations(Pretenses) are exploration systems that are generally conducted by druggists. These systems aim to grease rational use of medicines within our cases. Basically, furnishing perceptivity on how medicines are used in cases and observing defining patterns by our croakers. Pretenses are occasionally considered as medicine checkups because druggists are icing the use of drug is applicable. In addition, druggists also conduct experimental checks that are aimed at probing cases ' or croakers ' perspectives and stations towards specifics. Results attained from checks are used to ameliorate the services that we give to our cases. presently, NCC's oncology drugstore is conducting two checks. They're aimed at probing cases ' use of reciprocal and indispensable specifics and on cases ' perspective on safe running of oralanti-cancer medicines. veritably frequently, drugstore scholars who are adequately trained to conduct exploration are assigned to survey the cases. We'd like to take this occasion to thank all our cases who have acceded to share in the survey

12. FUTURE ASPECTS

India has applied product patents considering the fact that 2005, which will lead to widening of the market for indigenous as they will have the authenticity of internationally identified product patents. Product patent safety will motivate multinational corporations to import technology into India

to strengthen new products. These trends will open up expanded opportunities for the scientific trials of bio-tech and medicinal products. India is hastily improving upon this state of affairs as it seeks to one day emerge as a world chief in the CRO industry [12]. Sponsors are searching at India to leverage the excessive price of trials in the U.S. and Europe, and to decrease time to market. An entry-level medical researcher incomes simply onetenth as lots as a extra skilled colleague from his or her Indian business enterprise should nonetheless be hired by way of a U.S. or European sponsor at a 20–25% financial savings for the sponsor versus the counterpart overseas [13]. If India's medical trial commercial enterprise grows to 10% of the scope considered in the U.S. via 2015, then the industry will want about 50,000 recruits. India has a big pool of scientific, pharmaceutical, and scientific talent, however the provide of skilled gurus in India is about one-tenth of its demand [14].

13. DISCUSSION & CONCLUSION

A clinical trial for any new medicine follows under the guidelines of ICH and GCP, clinical trial are conducted in mortal levies for evidence of useful parcels of new medicine. After preclinical development, investigational new medicine passes through clinical phases I, II, III and IV. These phases give in detail explanation of pharmacokinetic, pharmacodynamic profile and side effect which may be dangerous or salutary, adverse effect and post marketing surveillance.,

To provide sufferers the most wonderful and most secure treatments possible, it is essential to understand the key ideas worried in performing scientific trials. The interest by using the mass media to safety-based drug withdrawal (amounting to about 1.5 tablets per year since 199351) emphasizes this point. Understanding the moral precepts and regulations behind trial designs might also additionally assist key stakeholders reply to future lookup dilemmas at home and abroad. Moreover, well-designed and accomplished medical trials can contribute significantly to the country wide effort to enhance the effectiveness and effectivity of fitness care in the United States. Through rigorous practices utilized to novel drug improvement and approval, doctors and sufferers can hold self belief in the cures prescribed.

REFERENCES

[1] Information about clinical trial. Available from URL http//www.temple.edu/pascope/about_trials.html

[2] Clinical trial wikipedia, the free encyclopedia. Jan 28 2008. Available from URL : http//en.wikipedia.org/wiki/clinical_trial. 28 Jan 2008.

[3] KulkarniS.K., Hand Book of Experimental Pharmacology, 3rd ed, Vallabh Prakashan New Delhi, , 21.

[4] ItkarS., Pharmaceutical Management, 3rd ed, Nirali Prakashan, Pune, 2007,13.4-13.5.

[5] ICH Harmonised triplex Guideline for Good Clinical Practice ' Academy For Clinical Excellenge'.

[6] Pharmacist Career Profile Clinical Research/ Investigational medicine, Available from URL: http//en.wikipedia.org/wiki/Randomized_controlled_trial.

[7] Barar,F.S.K., Essential of Pharmacotherapeutics. 4 thed,S. Chand and Company Ltd; New Delhi, 2007, - 59.

[8] Allen,L. V, Poporich,N. G, AnselH.C., Pharmaceutical Dosage Forms and Drug Delivery System, 8th ed, B I PublicationsPvt.Ltd.; New York, 2005, 45, 64- 65.

[9] Satoskar,R.S., Bhandar,S.D., Ainapure,S.S., Pharmacology and Pharmacotherapeutic. 8th ed, Popular Prakashan, Mumbai, 2003, 64.

[10] Pharmacist Role in clinical trial Avaliable from URLhttp//www.nccs.com.sg/pbcation/tomorrow/mar 08/pharmacy.

[11] R., H. American Recovery and Reinvestment Act of 2009. 1st ed. 2009.

[12] http://www.pharmainfo.net

[13] U. Sahoo, The Monitor, 2005, 19(4), 37

[14] A. Bhatt, U. Sahoo, Pharmabiz, 2004, 2, 26.

[15] Issa AM, Phillips KA, Van Bebber S, et al. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf. 2007; 2(3):177–185. [PubMed: 18690965]

[16] https://www.google.com/imgres?imgurl=https%3A%2F%2Fi.ibb.co%2Fr22QH2j%2Fclinical-trial-phases-graphic.jpg&imgrefurl=https%3A%2F%2Fcancergrace.org%2Ffind-clinical-trials&tbnid=41o00FWsCE2LaM&vet=1&docid=4VnZXsdpadqXtM&w=540&h=559&hl=en-GB&source=sh%2Fx%2Fim